SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine
NVX 1.065-0.9%Jan 21 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Strange who wrote (251)1/30/1998 9:48:00 AM
From: andy harrison  Read Replies (1) of 507
 
Rick:
From what I understand on this matter, you are totally wrong.
The other accellular DTaP (excluding NVX) use pieces of the killed
cell of the pertussis bacteria to stimulate the
immuned response. NVX is the only one that uses a highly purified
concentrated toxoid to produce the immune response. THe idea of
using the toxoid (NVX) was used in order to eliminate the major
side effects. As a matter of fact, this was the biggest controversy
before the trials started whether a toxoid could stimulate sufficient
immune response and now we see it can.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News